Jerry:
>>You have understanding way beyond my simple knowledge of physical chemistry.<<
It is only my best guess.
Because I was bit surprised by SU101 cancer data coming solely from PDGF-R activity inhibitor. As you know, leflunomide is at the end of Phase III for RA, by Hoechst. Leflunomide has several bio-chemical activity: 1) reduction of the Pyrimidine NTP level (inhibition of the pyrimidine nuscleotide synthesis, suppress T-cells proliferation by DNA synthesis control), 2) inhibition of the src-family tyrosine kinase activity (grow factor receptors family tyrosine kinase: EGF-R, PDGF-R, VEGF-R Flt/KDR,..), 3) inhibition of the dihydroorotate dehydrogenase (immunomodulatory activity), 4) prostaglandin endoperoxide H synthase (inhibition of the Prostaglandin E2 synthesis, anti-inflammatory),...
So, I can't say that I understand what is going on with SU101. However, I think that all this development are positive for SUGN and their anti-cancer drugs SU101 and SU5416.
mz |
